TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12440337
Drug: Vaginal suppositoria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositoria of 100 mg Metronidazole (Arilin rapid) for 2 days
Study: 9505164
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 7 g of sugar beet fiber
Study: 2205342
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors added to digoxin and diuretics
Study: 293141
Drug: Plasma THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma THC concentrations < 5.0 ng/mL
Study: 293141
Drug: Plasma THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma THC concentrations 5.0 to 10.0 ng/mL
Study: 293141
Drug: Plasma THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma THC concentrations > 10.0 ng/mL
Study: 27973337
Drug: Intra-arterial administration
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of nitroglycerine plus verapamil
Study: 21175446
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg)
Study: 17158228
Drug: Pravastatin (PV)
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin (PV) + Idarubicin (Ida) + high-dose cytarabine (Ara-C)
Study: 15150303
Drug: IP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP regimen (continuous portal vein infusion of 5‐fluorouracil at 500 mg/m2 daily for 7 days)
Study: 15150303
Drug: SY regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY regimen (six 28-day courses of systemic leucovorin at 100 mg/m2 daily on days 1-5 followed by systemic bolus 5‐fluorouracil at 370 mg/m2 daily on days 1-5)
Study: 29565716
Drug: Maltodextrin oral
Normalized name: maltodextrin ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin oral snack
Study: 7501717
Drug: Patient-controlled medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled medication delivery
Study: 2305603
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day ciamexone
Study: 28766537
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with bortezomib for 1 year
Study: 28766537
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with bortezomib
Study: 15124700
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (control group)
Study: 19085578
Drug: Indacaterol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 200 micro g
Study: 19085578
Drug: Indacaterol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 300 micro g
Study: 19085578
Drug: Indacaterol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 400 micro g
Study: 19085578
Drug: Indacaterol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 600 micro g
Study: 19085578
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 micro g twice daily (open-label after washout)
Study: 1590686
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of amphotericin B (45 min)
Study: 1590686
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of amphotericin B (4 h)
Study: 1590686
Drug: Both infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both infusion rates
Study: 30232048
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI (budesonide/glycopyrrolate/formoterol fumarate metered‐dose inhaler 320/18/9·6 μg)
Study: 18503906
Drug: Alteplase (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (2 mg or 4 mg based on infusion volumes of 0-50 mL or 51-100 mL, administered twice daily for 3 days)
Study: 18503906
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (administered twice daily for 3 days)
Study: 15922697
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg once nightly)
Study: 15922697
Drug: Fluticasone (88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (88 mug twice daily)
Study: 1890517
Drug: Rectal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal ketamine (5 mg/kg)
Study: 1890517
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam (0.30 mg/kg)
Study: 1890517
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.05 mg/kg) after induction
Study: 28964591
Drug: Trofinetide 35
Normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide 35 mg/kg twice daily for 14 days
Study: 28964591
Drug: Trofinetide 35
Normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide 35 mg/kg twice daily for 28 days
Study: 28964591
Drug: Trofinetide 70
Normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide 70 mg/kg twice daily for 28 days
Study: 26075487
Drug: Cariprazine 3-6
Normalized name: cariprazine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3-6 mg/d
Study: 25562205
Drug: Cariprazine 6-12
Normalized name: cariprazine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 6-12 mg/d
Study: 24227821
Drug: Weekly prophylaxis
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly prophylaxis (65 IU/kg, n = 24)
Study: 18163065
Drug: Moving pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moving pulse magnetic field (MPMF) treatment
Study: 11817775
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (150 mg/day)
Study: 11817775
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin (150 mg/day)
Study: 7822519
Drug: Calcipotriene ointment
Normalized name: Calcipotriene Ointment
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene ointment 0.005%
Study: 7662599
Drug: Immediate-release diltiazem
Normalized name: diltiazem Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release diltiazem 60 mg tid
Study: 7662599
Drug: Immediate-release diltiazem
Normalized name: diltiazem Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release diltiazem 120 mg tid
Study: 2628313
Drug: Oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prostaglandin E2 tablets
Study: 15608037
Drug: Long GnRH
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long GnRH agonist protocol
Study: 24571886
Drug: Bimatoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost/timolol fixed combination (0.03% bimatoprost and 0.5% timolol, once daily at 19:00 P.M.)
Study: 24571886
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment (0.03% bimatoprost followed by 0.5% timolol, once daily at 19:00 P.M.)
Study: 19855289
Drug: Bimatoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost/timolol fixed combination
Study: 10407505
Drug: Fluvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin therapy
Study: 3295315
Drug: colestipol-niacin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: colestipol-niacin therapy
Study: 2695381
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg t.i.d.
Study: 6802019
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg)
Study: 21823383
Drug: Ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.1 mg/kg for children < 40 kg, 4 mg for children > 40 kg)
Study: 21823383
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 2 ml)
Study: 19145638
Drug: Chinese medicinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicinal herb complex (CCMH; a mixture of citronellol and extracts of G. lucidum, C. pilosula and A. sinensis)
Study: 17306441
Drug: Docetaxel+prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel+prednisolone (30 mg m(‐2) weekly during 5 of 6 wk + prednisolone 5 mg x 2 per os daily)
Study: 15082979
Drug: Methylprednisolone (steroid)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (steroid)
Study: 9824787
Drug: Tiagabine 4
Normalized name: tiaGABine 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 4 mg twice daily
Study: 9824787
Drug: Tiagabine 4
Normalized name: tiaGABine 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 4 mg twice daily with Erythromycin 500 mg twice daily
Study: 2140547
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg twice daily
Study: 10661703
Drug: Saphenous vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saphenous vein patch angioplasty
Study: 23549954
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (0.8 ± 0.1 mg/kg per day for 3 days; cycles per year 2.0 ± 0.1; duration 7.3 ± 1.1 years; n = 5)
Study: 16968960
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of pantoprazole
Study: 16968960
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of pantoprazole
Study: 9416720
Drug: M-6-G (Dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-6-G (Dosage B: 0.029 mg/kg bolus + 0.014 mg x kg(‐1) x h(‐1) infusion)
Study: 9416720
Drug: M-6-G (Dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-6-G (Dosage C: 0.044 mg/kg bolus + 0.022 mg x kg(‐1) x h(‐1) infusion)
Study: 9416720
Drug: Morphine (Dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (Dosage D: 0.14 mg/kg bolus + 0.05 mg x kg(‐1) x h(‐1) infusion)
Study: 9416720
Drug: M-6-G combined
Normalized name: 6-amyl-m-cresol
DrugBank: Amylmetacresol (DB13908)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-6-G combined with morphine (Dosage E: A + D)
Study: 12095079
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg procyclidine
Study: 12095079
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg procyclidine
Study: 27861362
Drug: Naloxone (3.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (3.25 mg/kg, 4 mg/mL)
Study: 19660910
Drug: Chlorella supplementation
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella supplementation (6.3g daily for 6 weeks)
Study: 12499329
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg lysine x kg(‐1) x d(‐1)
Study: 12145014
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lysine x kg(‐1) x d(‐1)
Study: 12145014
Drug: 28 mg
Normalized name: aspirin 228 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 mg lysine x kg(‐1) x d(‐1)
Study: 15739214
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine
Study: 2872429
Drug: Intravenous ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ritodrine hydrochloride
Study: 27296780
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without ultrasound visual feedback
Study: 12913401
Drug: Early eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early eptifibatide administration
Study: 12913401
Drug: Both early
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both early and late eptifibatide administration
Study: 1600595
Drug: Cyclophosphamide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (400 mg/m2 given i.v. on day -7)
Study: 4065193
Drug: L-644,122 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-644,122 administered intravenously to healthy volunteers
Study: 4065193
Drug: L-644,122 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-644,122 administered by mouth to mild hypertensives
Study: 4065193
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravenous L-644,122
Study: 18179758
Drug: Hospital-supervised program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-supervised program of chest physical therapy (13 patients)
Study: 15131541
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy with low-dose tenectaplase and eptifibatide
Study: 8583094
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg i.v. every 12 h
Study: 2147631
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg day-1
Study: 15234277
Drug: Cevimeline, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevimeline, 20 mg three times daily
Study: 15234277
Drug: Cevimeline, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevimeline, 30 mg three times daily
Study: 7433897
Drug: Cimetidine, 400
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 400 mg at bedtime
Study: 30367939
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (100,000 IU bolus followed by 4000 IU/d) in individuals with greater vitamin D deficiency (25(OH)D < 30 nmol/L)
Study: 18644685
Drug: Naltrexone 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for 11 weeks, plus placebo sertraline
Study: 18644685
Drug: Naltrexone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone with sertraline
Study: 17875198
Drug: Acupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture + proton pump inhibitor
Study: 14734123
Drug: Darusentan (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan (mean dose 144 +/- 125 mg/day, dosages of 30 mg, 100 mg, or 300 mg for 3 weeks)
Study: 25743829
Drug: High-frequency microsatellite
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency microsatellite instability without adjuvant chemotherapy
Study: 23246249
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of oral doxycycline (Doxy-14)
Study: 21444113
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 to 600 mg/d)
Study: 12612033
Drug: PAS(10 ms)
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS(10 ms) under the influence of dextromethorphan (an NMDA receptor antagonist).
Study: 12612033
Drug: PAS(10 ms)
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS(10 ms) under the influence of nimodipine (an L-type voltage-gated calcium-channel antagonist).
Study: 11028833
Drug: Tropisetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (5 mg) daily for 28 days
Study: 8649631
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) - enoxaparin 40 mg/0.4 ml
Study: 28582271
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate (CHO) loading (800 mL of water containing 100 g of CHO)
Study: 28582271
Drug: Placebo (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (800 mL of water)
Study: 22370487
Drug: Expanded workplace
Normalized name: Allogeneic, ex-vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells - cultured fraction (CF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expanded workplace depression treatment programs
Study: 22370487
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for major depressive disorder (MDD)
Study: 22370487
Drug: Detection and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection and treatment of depression among patients with chronic physical disorders
Study: 22370487
Drug: Early MDD
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early MDD treatment interventions
Study: 20852963
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of [¹H]MRSI and DCE-MRI
Study: 15813810
Drug: Nasal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroids (budesonide 400 microg daily)
Study: 15813810
Drug: Specific allergen
Normalized name: House dust specific allergen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific allergen immunotherapy (SIT)
Study: 12154417
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution therapy
Study: 19301989
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR
Study: 19250295
Drug: Comprehensive school‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive school‐based preventive oral health program
Study: 18162029
Drug: EE/DRSP (ethinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/DRSP (ethinyl estradiol 30 mug/day plus drospirenone 3 mg/day)
Study: 8037128
Drug: Atrioventricular junction
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrioventricular junction radiofrequency ablation plus pacemaker therapy (n = 12)
Study: 8037128
Drug: Pacemaker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacemaker therapy alone (n = 11)
Study: 29063853
Drug: Brachytherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy plus External Beam Radiation Therapy (EBRT)
Study: 23064441
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg TXA immediately before CS
Study: 9109749
Drug: Xanomeline high
Normalized name: Xanomeline
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline high dose (225 mg)
Study: 8225682
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg b.i.d. misoprostol
Study: 3512420
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir alone
Study: 3512420
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir plus co‐trimoxazole
Study: 27282261
Drug: PPI plus
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI plus rebamipide (300 mg/day)
Study: 27282261
Drug: PPI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI monotherapy (10 mg/day)
Study: 25035199
Drug: Hyperfractionation (HFX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionation (HFX) to 79.2 Gy in 66 fractions of 1.2 Gy given twice a day
Study: 11816915
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with verteporfin
Study: 8752779
Drug: Pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 30 mg before surgical incision (group A)
Study: 8752779
Drug: Pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 30 mg after abdominal incision (group B)
Study: 8752779
Drug: Pentazocine 60
Normalized name: pentazocine 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 60 mg after abdominal incision (group B)
Study: 7096142
Drug: NH4Cl (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NH4Cl (300 mg/kg body wt) to induce acidosis
Study: 26957103
Drug: Cedar Project
Normalized name: Cedar oil
DrugBank: Cedar oil (DB10917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cedar Project WelTel mHealth intervention (mobile phone, cellular plan, weekly two-way text messaging, support from Cedar Case Managers)
Study: 22349946
Drug: Ethanol treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol treatment for 0s (control group) with Adper™ Scotchbond™ Multi‐Purpose (Scotchbond)
Study: 22349946
Drug: Ethanol treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol treatment for 20s (Group 1) with hydrophobic adhesive
Study: 22349946
Drug: Ethanol treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol treatment for 60s (Group 2) with hydrophobic adhesive
Study: 22349946
Drug: Ethanol treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol treatment for three 60s periods (Group 3) with hydrophobic adhesive
Study: 17714101
Drug: Drug therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapies for neuropathic pain
Study: 10172792
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 100 mg twice daily for 5 days
Study: 10172792
Drug: Phenoxymethylpenicillin 1
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 1 MIU 3 times daily for 10 days